News

ODU, EVMS, Sentara Name Partnership Executive Director

Kevin Leslie has been named executive director of the new Hampton Roads Biomedical Research Consortium (HRBRC), a partnership between Old Dominion University, Eastern Virginia Medical School (EVMS) and Sentara Healthcare.

Recently approved by Gov. Ralph Northam and the General Assembly, the HRBRC aims to strengthen the relationship among the three institutions and to jump start more research collaboration as well as to ultimately generate health-care improvements in Hampton Roads, making it more efficient and less expensive.

“The state has commissioned a study to recommend the optimal structure for our partnership. But for now, the consortium’s first order of business is to mine the region’s vast collection of health-care data – stripped of personal information,” said Morris Foster, Old Dominion’s vice president for research who helped establish the framework for the consortium. “The resulting algorithms and applications could produce extensive benefits for our region, including wearable devices to monitor health and more pinpointed recommendations for patients.”

Leslie was previously the associate director of VCU Ventures, a division at Virginia Commonwealth University that helps faculty and staff launch startup companies with an eye to innovation in health care. He received his Ph.D. in biophysics from VCU and has worked as a senior scientist in the private sector.

“Kevin knows the biotech ecosystem in the commonwealth, and he’s well-versed in sources of funding opportunities, both on the public and private sides,” Foster said. “Under his direction, the consortium stands poised to build the biotech sector in Hampton Roads and catalyze more innovation.”

Dr. Jordan Asher, Sentara’s chief physician executive, expressed his appreciation for the commonwealth’s support and added: “We are excited to collaborate with ODU and EVMS in this new endeavor to advance research in the Hampton Roads region that will improve the health of our communities.”

“We welcome Kevin to the region and are excited to collaborate with him and our partners in the HRBRC to advance biohealth development and innovation,” said William Wasilenko, vice dean for research at EVMS.

Leslie believes the region as a whole could see a big economic-development boost.

“The HRBRC embodies what drives and excites me: the challenges of a startup, the pursuit of health equity, community building and working with diverse and talented people,” Leslie said. “The foundational pieces of a world-class pipeline are in place. Now, we finally have the opportunity to coordinate them in earnest.

“We’re going to advance science and medicine while holistically strengthening Hampton Roads, and I’m honored to be a part of it.”

According to Foster, Old Dominion’s faculty will benefit from increased opportunities for collaboration with colleagues at EVMS and Sentara and will become more competitive for NIH grants.

“Graduate students will also gain valuable experience in projects that will strengthen their dissertations and their scientific potential after they leave ODU,” he said.

Recent News

09/30/2026

Activation Capital Recognizes President Michael Rao’s 17 Years of Leadership as Authority Board Chair, Names Paul Nolde as New Chair

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced the election of Paul Nolde as chair of the Authority Board, succeeding Virginia Commonwealth University President Michael Rao, Ph.D., who has served as chair since 2009. Rao will remain an active member of the board, continuing his longstanding support of Activation …

09/22/2026

ATCC to Lead Lifecycle Management of Military Medical Countermeasures Under 10-Year Department of War Contract

ATCC has been awarded a 10-year Department of War (DOW) contract to coordinate lifecycle management of medical countermeasures (MCMs) developed to protect U.S. military personnel from chemical and biological threats. Under this contract, ATCC supports the mission of the Rapid Access to Products in Development (RAPID) program to enable MCM preparedness against chemical and biological …

09/22/2026

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. …